Mp54-16 Survival Analysis of Patients With Muscle Invasive Bladder Cancer Not Suitable for Treatment With a Curative Intent

Abstract

variants were found mostly as pure variants. With a median follow up of 6.5 years, patients who harbored pure variant were found at multivariablean alyses with lower survival outcomes when compared with pure urothelial carcinoma (all p<0.01). Conversely no differences were found between mixed variant vs. pure urothelial at multivariable Cox regression analyses predicting recurrence, CSM and OM (all p>0.1).CONCLUSIONS: Presence of histologic variants at RC is a common finding accounting for approximately 30% of specimens. In this setting, the presence of a pure variant but not the presence of mixed variant with urothelial carcinoma is related to a detrimental effect on survival outcomes after RC.

Safety, Tolerability, and Preliminary Efficacy of TAR-200 in Patients With Muscle-invasive Bladder Cancer Who Refused or Were Unfit for Curative-intent Therapy: A Phase 1 Study

“…Rates of clot evacuation and blood transfusion were considerably lower than in patients who historically received no curative-intent treatment. 24 TEAEs observed in this elderly and frail cohort of patients with MIBC were as expected, with no unanticipated safety issues attributed to treatment with TAR-200.…”

“…15 The median OS observed with TAR-200 in this study of elderly and frail patients compares favorably with multiple retrospective studies demonstrating that patients with MIBC who did not receive or were ineligible for curative-intent therapy have a median OS of ≤12 months. 12,14,24,25 We interpret this comparison cautiously as our cohort had primarily T2 disease, and the historical data comprised patients with T2 and T3 disease. Figure 5 seems to corroborate these findings, showing that early progression events were associated with survival <12 months, whereas responders appear to benefit from improved survival.…”